12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Daclatasvir: Phase II start

Medivir AB (SSE:MVIR B, Huddinge, Sweden) said an open-label Phase II trial will begin this month to evaluate daily oral 150 mg TMC435 from it and Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) in combination with daily oral 30 mg daclatasvir from Bristol-Myers Squibb for 12 or 24 weeks...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >